Starpharma was featured on the back of its full year results with the well respected business commentator saying “Time to cross the fingers, keep the faith and buy.”

Starpharma today released its annual report and financial results for the year ended 30 June 2012.

 Financial Results

• Cash burn (cash outflows before new capital) for the year $9.9M
• Cash position at end of year $42.8M
• A$35 million placement and share purchase plan
• Reported loss $13.7M

In this issue:

›   VivaGel^® BV trials on track for completion in 2012
›   NDA ready – activities in place to support the BV approval submission
›   Leading the way for Australian innovations
›   Starpharma’s drug delivery program progresses into exciting new areas
›   Crop protection agreement signed with Nufarm
›   Market recognition of Starpharma

Download: Shareholder Update: August 2012 ( pdf file, 1MB)

  Nufarm Australia and Starpharma  today announced the signing of an agreement under which the parties will apply Starpharma’s Priostar^® dendrimer technology to develop innovative crop protection formulations for Nufarm’s product portfolio.

Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 June 2012.

•           CEO Dr Jackie Fairley presenting at the Nomura Biotech Conference for institutional investors in Sydney, 24th July 2012.

•           Presentation to include update on the rapidly advancing VivaGel^® Bacterial Vaginosis Program, and advancements in Drug Delivery and Agrochemicals Programs.

View presentation here

Starpharma today provided an update on the developments within its substantial drug delivery program.

Key Points:

>    Dendrimer-docetaxel program advancing rapidly; clinical trial expected to commence in 2013

>    Successful application of dendrimers to a number of important classes of drugs including small molecules, antibodies and proteins

>    Analysis shows Starpharma’s dendrimers applicable to more than 50% of top-selling pharmaceuticals - highlighting versatility and potential to develop improved formulations

Herald Sun Business Journalist John Beveridge examines Starpharma’s success in reaching commercial milestones and recruiting participants for its VivaGel trials in his In the Black column.

‘Three pivotal clinical trials are now almost completely stocked with test subjects, primarily to check the effectiveness of Starpharma's VivaGel at preventing and treating the common disorder bacterial vaginosis.

These trials are at the very sharp end of proceedings - phase two and phase three before the US Food and Drug Administration - and results should be in before Christmas.

That puts Starpharma chief executive Dr Jackie Fairley in a strong position to negotiate a lucrative deal next year with a large pharmaceutical partner to add marketing and distribution muscle to some excellent Australian-developed science.’

Go to the article (external link)

• Recruitment 100% complete for VivaGel^® Phase 2 prevention study for bacterial vaginosis (BV)
• Recruitment for two pivotal Phase 3 BV treatment studies proceeding rapidly with enrolment of the first trial now 100% complete
• Phase 3 treatment trials and the Phase 2 prevention trial all expected to complete in 2H CY2012.
• Activities to support NDA submission, including manufacturing scale up and validation, well advanced

Key points

• > Enrolment passes 60% for VivaGel^® Phase 3 BV treatment trials
• > Trials well on track for completion in 2012
• > One of the trials has already enrolled more than 80% of subjects